Search
forResearch 10 of 1000+
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Erlotinib-Associated Alopecia in a Lung Cancer Patient
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →